Strategic partnerships HALIX collaborates with vaccine developers and large pharma, including recent tie-ups with AstraZeneca and RocketVax, indicating a readiness to engage in co-development and manufacturing agreements for biologics and viral products with global reach.

Vaccine and viral vectors With expertise in viral vectors, vaccines, recombinant proteins, and antibodies, HALIX is well-positioned to pursue CDMO opportunities in COVID-19, influenza, and other infectious disease programs as well as gene therapy vector manufacturing.

Leadership and growth New CEO appointment and active business development leadership signal a growth trajectory and a proactive sales outreach, suggesting momentum for expanding service scope, capacity, and international projects.

Clinical to commercial HALIX has experience spanning clinical to commercial scale manufacturing, including partnerships for commercial vaccine production, which can be leveraged to target sponsors transitioning from clinical trials to market launch.

Global readiness Partnerships with multinational players and a GMP-ready Leiden facility position HALIX as a reliable partner for global supply chains, enabling conversations around scale-up, regulatory compliance, and pandemic preparedness contracts.